Lab Innovations 2015 Announces New Partnership with ELRIG
News Oct 30, 2015
Lab Innovations 2015, which takes place at Birmingham’s NEC on 4 & 5 November, has announced that the European Laboratory Research & Innovation Group (ELRIG) will be hosting its own conference programme live on the show floor. New for 2015, the content-rich seminar sessions will feature a snap shot into ELRIG’s ‘Drug Discovery Programme’.
This free-to-attend conference will provide a fantastic communication and learning opportunity for scientists engaged in research fields across the drug discovery spectrum, bringing together the fields of academia, biotech, vendors and pharmaceutical.
Mark Wigglesworth, Director of High Throughput Screening at AstraZeneca, will chair both days of the conference, kick starting the event with opening remarks, before presenting on ‘The challenges with Drug Discovery’.
Attendees will also be able to hear Lee Wenwa, Director of the Disease Foundations Network programme at the Structural Genomics Consortium, discussing ‘A new model for drug discovery’, while David Poyner, Reader in Pharmacology at Aston University will present the ‘Modern techniques in GPCR measurement’.
Ian Willox, Business Development Manager at DiscoveRx, will look at ‘Applying cell based assays’, whilst Paul Kendall, Business Development Manager at Festo, will explore the ‘Engineering solution to life science challenges’. Visitors will also hear from Adrian Kinkaid, Chief Executive Officer at MIP Diagnostics Ltd, on ‘Plastic antibodies’.
Commenting on the new partnership with ELRIG, Daniel Gray, Event Manager said: “We are delighted to welcome ELRIG onboard as a show partner for 2015. It’s an exciting new element to the show providing scientists involved in drug discovery with the opportunity to hear about relevant topics in their field and research. This partnership expands on the wealth of content that we already provide to our visitors, whilst also providing brilliant networking opportunities between like-minded individuals.”
A new method of selectively binding proteins to nanoparticles has been published. The nanoparticles automatically recognize specific peptides, i.e. small proteins, and enter into highly selective binding with them. Among the model peptides which the researchers examined were amyloids. The researchers hope that the mechanism they have discovered might provide a new approach to treating diseases in which such deposits occur, such as Alzheimer’s disease.READ MORE
International Conference on Clinical Trials & Pharmacovigilance
Feb 28 - Mar 01, 2019